This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dammerman, M. Articles by Breslow, J. L. Search for Related Content PubMed PubMed Citation Articles by Dammerman, M. Articles by Breslow, J. L.

(Circulation. 1995;91:505-512.)
© 1995 American Heart Association, Inc.

Articles

Genetic Basis of Lipoprotein Disorders

Marilyn Dammerman, PhD; Jan L. Breslow, MD

From the Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, New York, NY.

Correspondence to Jan L. Breslow, MD, Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, 1230 York Ave, New York, NY 10021.

Key Words: atherosclerosis • lipoproteins • apolipoproteins • genes

	Introduction

 
Lipoprotein disorders result from abnormal synthesis, processing, or catabolism of plasma lipoprotein particles. These particles consist of a core of cholesterol ester and triglyceride enclosed in a coat of phospholipids and apolipoproteins. More than half of patients with angiographically confirmed coronary artery disease (CAD) before age 60 years have a familial lipoprotein disorder.¹ The association is most striking among younger patients and declines with increasing age at first myocardial infarction (MI). This suggests the presence of genetic factors that accelerate age-associated cardiovascular changes seen in the general population.² Severe hyperlipidemia (total cholesterol >300 mg/dL or triglycerides >500 mg/dL) usually indicates a genetic disorder, and xanthomas almost always signal an underlying genetic defect. These findings warrant examination of the patient's first-degree relatives.² Four types of lipoprotein abnormalities are observed: elevated LDL cholesterol; reduced HDL cholesterol, usually with increased triglycerides and very-low-density lipoprotein (VLDL) cholesterol; elevated levels of chylomicron remnants and intermediate-density lipoproteins (IDL); and elevated levels of lipoprotein (a) [Lp(a)] particles.³ Lipoprotein transport genes have been implicated in each of these abnormal lipoprotein phenotypes (Table 1).

View this table: [in this window] [in a new window]   Table 1. Genetic Factors in Lipoprotein Abnormalities

	Elevated LDL Cholesterol

 
Cholesterol levels >240 mg/dL are associated with a threefold increased risk of death from ischemic heart disease in men relative to cholesterol levels <200 mg/dL, and there is a continuous risk gradient as cholesterol rises.² Elevated total cholesterol primarily reflects elevated LDL cholesterol, which constitutes 70% of plasma cholesterol. Disorders characterized by elevation of cholesterol alone are classified as Fredrickson type IIa hyperlipoproteinemia.

LDL particles are a . . . [Full Text of this Article]

This article has been cited by other articles:

				R. A. Hegele, M. R. Ban, N. Hsueh, B. A. Kennedy, H. Cao, G. Y. Zou, S. Anand, S. Yusuf, M. W. Huff, and J. Wang A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia Hum. Mol. Genet., November 1, 2009; 18(21): 4189 - 4194. [Abstract] [Full Text] [PDF]

				J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF]

				C. Atkinson, W. Oosthuizen, S. Scollen, A. Loktionov, N. E. Day, and S. A. Bingham Modest Protective Effects of Isoflavones from a Red Clover-Derived Dietary Supplement on Cardiovascular Disease Risk Factors in Perimenopausal Women, and Evidence of an Interaction with ApoE Genotype in 49-65 Year-Old Women J. Nutr., July 1, 2004; 134(7): 1759 - 1764. [Abstract] [Full Text]

				C. L. Welch, S. Bretschger, P.-Z. Wen, M. Mehrabian, N. Latib, J. Fruchart-Najib, J. C. Fruchart, C. Myrick, and A. J. Lusis Novel QTLs for HDL levels identified in mice by controlling for Apoa2 allelic effects: confirmation of a chromosome 6 locus in a congenic strain Physiol Genomics, March 12, 2004; 17(1): 48 - 59. [Abstract] [Full Text] [PDF]

				S. V. Anisimov, M. V. Volkova, L. V. Lenskaya, V. K. Khavinson, D. V. Solovieva, and E. I. Schwartz Age-Associated Accumulation of the Apolipoprotein C-III Gene T-455C Polymorphism C Allele in a Russian Population J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2001; 56(1): 27B - 32. [Abstract] [Full Text]

				S.-H. H. Juo, Z. Han, J. D. Smith, L. Colangelo, and K. Liu Common Polymorphism in Promoter of Microsomal Triglyceride Transfer Protein Gene Influences Cholesterol, ApoB, and Triglyceride Levels in Young African American Men : Results From the Coronary Artery Risk Development in Young Adults (CARDIA) Study Arterioscler Thromb Vasc Biol, May 1, 2000; 20(5): 1316 - 1322. [Abstract] [Full Text] [PDF]

				S. C. Whitman, C. A. Argmann, C. G. Sawyez, D. B. Miller, R. A. Hegele, and M. W. Huff Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-{gamma} J. Lipid Res., June 1, 1999; 40(6): 1017 - 1028. [Abstract] [Full Text]

				S. C. Whitman, S. L. Hazen, D. B. Miller, R. A. Hegele, J. W. Heinecke, and M. W. Huff Modification of Type III VLDL, Their Remnants, and VLDL From ApoE-Knockout Mice by p-Hydroxyphenylacetaldehyde, a Product of Myeloperoxidase Activity, Causes Marked Cholesteryl Ester Accumulation in Macrophages Arterioscler Thromb Vasc Biol, May 1, 1999; 19(5): 1238 - 1249. [Abstract] [Full Text] [PDF]

				D.J. Galton and G.A.A. Ferns Genetic markers to predict polygenic disease: a new problem for social genetics QJM, April 1, 1999; 92(4): 223 - 232. [Abstract] [Full Text] [PDF]

				A. Mamontova, S. Seguret-Mace, B. Esposito, C. Chaniale, M. Bouly, N. Delhaye-Bouchaud, G. Luc, B. Staels, N. Duverger, J. Mariani, et al. Severe Atherosclerosis and Hypoalphalipoproteinemia in the Staggerer Mouse, a Mutant of the Nuclear Receptor ROR{alpha} Circulation, December 15, 1998; 98(24): 2738 - 2743. [Abstract] [Full Text] [PDF]

				S. C. Whitman, C. G. Sawyez, D. B. Miller, B. M. Wolfe, and M. W. Huff Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL J. Lipid Res., May 1, 1998; 39(5): 1008 - 1020. [Abstract] [Full Text]

				W. Huang, J. Sasaki, A. Matsunaga, H. Nanimatsu, K. Moriyama, H. Han, M. Kugi, T. Koga, K. Yamaguchi, and K. Arakawa A Novel Homozygous Missense Mutation in the Apo A-I Gene With Apo A-I Deficiency Arterioscler Thromb Vasc Biol, March 1, 1998; 18(3): 389 - 396. [Abstract] [Full Text] [PDF]

				P. Clarkson, D. S. Celermajer, A. J. Powe, A. E. Donald, R. M. A. Henry, and J. E. Deanfield Endothelium-Dependent Dilatation Is Impaired in Young Healthy Subjects With a Family History of Premature Coronary Disease Circulation, November 18, 1997; 96(10): 3378 - 3383. [Abstract] [Full Text]

				S. C. Whitman, D. B. Miller, B. M. Wolfe, R. A. Hegele, and M. W. Huff Uptake of Type III Hypertriglyceridemic VLDL by Macrophages Is Enhanced by Oxidation, Especially After Remnant Formation Arterioscler Thromb Vasc Biol, September 1, 1997; 17(9): 1707 - 1715. [Abstract] [Full Text]

				T. Planella, M. Cortes, C. Martinez-Bru, F. Gonzalez-Sastre, and J. Ordonez-Llanos Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia Clin. Chem., May 1, 1997; 43(5): 808 - 815. [Abstract] [Full Text] [PDF]

				P. W.F. Wilson, E. J. Schaefer, M. G. Larson, and J. M. Ordovas Apolipoprotein E Alleles and Risk of Coronary Disease: A Meta-analysis Arterioscler Thromb Vasc Biol, October 1, 1996; 16(10): 1250 - 1255. [Abstract] [Full Text]